TKT and chronic myelogenous leukemia, BCR-ABL1 positive: In CML the TK inhibitors are almost certainly making a substantial impact on survival but this is not yet being seen in population based studies, partly because the data is too immature and partly because as a population of all patients with leukaemia the numbers are small.